Lineage Cell Therapeutics Inc. [LCTX] President and CEO makes an insider acquire of 6,400 shares worth 9,792.

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Lineage Cell Therapeutics Inc. shares valued at $9,792 were purchased by Culley Brian M on Mar 31. At $1.53 per share, Culley Brian M acquired 6,400 shares. The insider’s holdings grew to 97,787 shares worth approximately $0.17 million following the completion of this transaction.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Also, Amin Dipti purchased 35,000 shares, netting a total of over 57,050 in proceeds. Following the buying of shares at $1.63 each, the insider now holds 35,000 shares.

Before that, Culley Brian M had added 5,250 shares to its account. In a trade valued at $7,245, the President and CEO bought Lineage Cell Therapeutics Inc. shares for $1.38 each. Upon closing the transaction, the insider’s holdings increased to 5,250 shares, worth approximately $0.14 million.

As published in their initiating research note from B. Riley Securities on June 14, 2022, Lineage Cell Therapeutics Inc. [LCTX] has been a Buy and the price target has been revised to $4. This represents a 55.75% premium over Thursday’s closing price. Analysts at Noble Capital Markets started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid August. As of March 31, 2021, Cantor Fitzgerald has initiated its “an Overweight” rating for LCTX.

Analyzing LCTX’s Price Performance

On Thursday, Lineage Cell Therapeutics Inc. [AMEX: LCTX] rose 8.59% to $1.77. The stock’s lowest price that day was $1.63, but it reached a high of $1.79 in the same session. During the last five days, there has been a surge of approximately 9.26%. Over the course of the year, Lineage Cell Therapeutics Inc. shares have dropped approximately -27.76%. Shares of the company reached a 52-week high of $2.5750 on 01/03/22 and a 52-week low of $1.1000 on 05/16/22. A 50-day SMA is recorded $1.4994, while a 200-day SMA reached $1.6891. Nevertheless, trading volume fell to 1.02 million shares from 0.2 million shares the previous day.

Support And Resistance Levels for Lineage Cell Therapeutics Inc. (LCTX)

According to the 24-hour chart, there is a support level at 1.6700, which, if violated, would cause prices to drop to 1.5700. In the upper region, resistance lies at 1.8300. The next price resistance is at 1.8900. RSI (Relative Strength Index) is 62.49 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.0279, which suggests the price will decrease in the coming days. Percent R is at 8.70%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Lineage Cell Therapeutics Inc. subject to short interest?

Stocks of Lineage Cell Therapeutics Inc. saw a sharp steep in short interest on Jul 14, 2022 dropping by -3.96 million shares to 4.97 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 8.93 million shares. A decline of -79.68% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.14 of the overall float, the days-to-cover ratio (short ratio) decline to 3.14.

Which companies own the most shares of Lineage Cell Therapeutics Inc. (LCTX)?

According to Broadwood Capital, Inc. filings, the company currently owns 34,935,485 shares, which is about 20.58% of the total LCTX shares outstanding. The investor’s shares have appreciated by 930,106 from its previous 13-F filing of 34005379.0 shares. With the completion of the sale transaction, BlackRock Fund Advisors’s stake is now worth $14,452,165. Greenway Partners LP reduced a -0.21% interest valued at $10.86 million while The Vanguard Group, Inc. purchased a 13,992 stake. A total of 125,750 shares of Lineage Cell Therapeutics Inc. were bought by Defender Capital LLC during the quarter, and -54,178 were sold by Geode Capital Management LLC. In its current portfolio, British & American Investment Tru holds 2,271,053 shares valued at $3.59 million.

In terms of Lineage Cell Therapeutics Inc. share price expectations, FactSet research, analysts set an average price target of $6.00 in the next 12 months, up nearly 268.1% from the previous closing price of $1.63. Analysts anticipate Lineage Cell Therapeutics Inc. stock to reach $8.00 by 2022, with the lowest price target being $4.00. In spite of this, 7 analysts ranked Lineage Cell Therapeutics Inc. stock as a Buy at the end of 2022.

LEAVE A REPLY

Please enter your comment!
Please enter your name here